Tisotumab

• CAT Number: I042436
• CAS Number: 1418628-81-5
• Purity: ≥95%

Tisotumab (Cat No.: I042436) is a monoclonal antibody that targets tissue factor (TF), a transmembrane glycoprotein involved in coagulation and tumor progression. It is the antibody component of tisotumab vedotin, an antibody-drug conjugate (ADC) used in oncology. By binding to TF, tisotumab delivers cytotoxic agents directly to cancer cells, minimizing off-target effects. This targeted therapy is especially promising in treating solid tumors such as cervical cancer. Tisotumab aids in research on tumor-targeted therapies, angiogenesis, and the role of TF in cancer biology.

Reference

[1]. Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22(5):609-619.
[Content Brief]